A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV)

  • Joseph D
  • Baltazar G
  • Jacquez R
  • et al.
N/ACitations
Citations of this article
15Readers
Mendeley users who have this article in their library.

Abstract

Background: Pneumonia leading to acute respiratory distress syndrome (ARDS) is one of the devastating consequences of coronavirus disease 2019 (COVID-19). Airway pressure release ventilation (APRV) has been described as beneficial in acute lung injury and ARDS. We hypothesized that utilizing APRV would be advantageous in the COVID-19 ARDS population. Methods: Prospective, observational, single-center study. Data were extracted on demographics, vasopressors, sedatives, analgesics, and oxygenation (PaO2/FiO2). A generalized linear mixed models analysis was performed to compare low tidal volume ventilation (LTV) with APRV for patients who required intubation due to ARDS from COVID-19 and who were managed with at least 48 consecutive hours of APRV in our surgical intensive care unit (SICU). Results: Twelve patients met criteria; two were on APRV mode from admission to the SICU and were not included in the study. Ten patients were analyzed and were primarily male (70%), average age of 64.5 6 12.9 years, and 70% were obese (average body mass index of 30.6 6 8.0 kg/m 2). There were no smokers in the sample, but two patients presented with underlying lung pathology. APRV was shown to significantly increase the PaO 2 /FiO 2 ratio by 30% (5% to 61%) (p ¼ 0.05) and was associated with up to a 12% (À26% to 5%) reduction in the level of F i O 2 and reduction in the use of vasopressor support (À59% [À83% to À2%]), sedatives (À15% [À29% to 2%]), and analgesics (À16% [À38% to 12%]). Conclusions: This pilot study showed that APRV was associated with decreases in FiO 2 , vasopressors, sedatives, and analgesic requirements with an increase in PaO 2 /FiO 2 ratio. In the current pandemic, where providers are grappling with ways to manage COVID-19 ARDS, APRV may be the optimal ventilator mode. Prospective randomized studies are required to validate whether use of APRV in the COVID-19 population leads to improved oxygenation and a subsequent decrease of ventilator days and length of stay.

Cite

CITATION STYLE

APA

Joseph, D. K., Baltazar, G. A., Jacquez, R. A., Islam, S., Stright, A., Divers, J., … Petrone, P. (2021). A Pilot Study of Patients With COVID–19-Related Respiratory Failure Utilizing Airway Pressure Release Ventilation (APRV). Innovations in Surgery and Interventional Medicine, 1(1), 3–8. https://doi.org/10.36401/isim-20-03

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free